Ho Choi1, JiHyeon Ryu2, Heenam Seo2, MinKu Kang3, Eunyoung Kim4. 1. Department of Pharmacy, Sun Hospital, Daejeon, South Korea. 2. Clinical Pharmacy and Evidence Based Practice Research Lab, College of Pharmacy, ChungAng University, Seoul, 156-756, South Korea. 3. College of Pharmacy, Woosuk University, Wonju-gun, South Korea. 4. Clinical Pharmacy and Evidence Based Practice Research Lab, College of Pharmacy, ChungAng University, Seoul, 156-756, South Korea. eykimjcb777@cau.ac.kr.
Abstract
BACKGROUND: A double maintenance dose of clopidogrel at 150 mg daily has been suggested as an effective alternative treatment for patients who have clopidogrel resistance. OBJECTIVE: To determine if a double maintenance dose of clopidogrel can overcome the low drug response rate observed in patients who have clopidogrel resistance while on a 75 mg daily standard maintenance dose of clopidogrel. METHODS: A retrospective analysis was conducted in South Korean patients who underwent a platelet function test and received a double maintenance dose of clopidogrel at a secondary medical institution between January 2011 and June 2012. The primary endpoint was to assess clopidogrel response using an adenosine diphosphate test after a double maintenance dose of clopidogrel. The secondary endpoint was the presence of factors that could affect response to clopidogrel. RESULTS: Of 389 patients identified, 77 patients were eligible for this study. Values from the adenosine diphosphate test decreased significantly in 63 patients (82%) after a double maintenance dose of clopidogrel (p < 0.001). A total of 37 patients (48%) overcame clopidogrel resistance. Concurrent disease appeared to be a contributory factor in clopidogrel resistance. CONCLUSION: A double maintenance dose of clopidogrel at 150 mg daily was associated with a reduction in adenosine diphosphate-induced platelet aggregation in South Korean patients who previously exhibited clopidogrel resistance.
BACKGROUND: A double maintenance dose of clopidogrel at 150 mg daily has been suggested as an effective alternative treatment for patients who have clopidogrel resistance. OBJECTIVE: To determine if a double maintenance dose of clopidogrel can overcome the low drug response rate observed in patients who have clopidogrel resistance while on a 75 mg daily standard maintenance dose of clopidogrel. METHODS: A retrospective analysis was conducted in South Korean patients who underwent a platelet function test and received a double maintenance dose of clopidogrel at a secondary medical institution between January 2011 and June 2012. The primary endpoint was to assess clopidogrel response using an adenosine diphosphate test after a double maintenance dose of clopidogrel. The secondary endpoint was the presence of factors that could affect response to clopidogrel. RESULTS: Of 389 patients identified, 77 patients were eligible for this study. Values from the adenosine diphosphate test decreased significantly in 63 patients (82%) after a double maintenance dose of clopidogrel (p < 0.001). A total of 37 patients (48%) overcame clopidogrel resistance. Concurrent disease appeared to be a contributory factor in clopidogrel resistance. CONCLUSION: A double maintenance dose of clopidogrel at 150 mg daily was associated with a reduction in adenosine diphosphate-induced platelet aggregation in South Korean patients who previously exhibited clopidogrel resistance.
Entities:
Keywords:
Clopidogrel resistance; High maintenance dose; South Korea
Authors: Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Carl L Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao; Jeffrey L Anderson; Alice K Jacobs; Jonathan L Halperin; Nancy M Albert; Ralph G Brindis; Mark A Creager; David DeMets; Robert A Guyton; Judith S Hochman; Richard J Kovacs; Frederick G Kushner; E Magnus Ohman; William G Stevenson; Clyde W Yancy Journal: Circulation Date: 2012-12-17 Impact factor: 29.690
Authors: Shamir R Mehta; Jean-Francois Tanguay; John W Eikelboom; Sanjit S Jolly; Campbell D Joyner; Christopher B Granger; David P Faxon; Hans-Jurgen Rupprecht; Andrzej Budaj; Alvaro Avezum; Petr Widimsky; Philippe Gabriel Steg; Jean-Pierre Bassand; Gilles Montalescot; Carlos Macaya; Giuseppe Di Pasquale; Kari Niemela; Andrew E Ajani; Harvey D White; Susan Chrolavicius; Peggy Gao; Keith A A Fox; Salim Yusuf Journal: Lancet Date: 2010-10-09 Impact factor: 79.321
Authors: Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol Journal: JAMA Date: 2011-03-16 Impact factor: 56.272
Authors: Paul A Gurbel; Richard C Becker; Kenneth G Mann; Steven R Steinhubl; Alan D Michelson Journal: J Am Coll Cardiol Date: 2007-10-23 Impact factor: 24.094
Authors: Dominick J Angiolillo; Antonio Fernandez-Ortiz; Esther Bernardo; Fernando Alfonso; Carlos Macaya; Theodore A Bass; Marco A Costa Journal: J Am Coll Cardiol Date: 2007-03-26 Impact factor: 24.094
Authors: Mohammed Ahmed Akkaif; Nur Aizati Athirah Daud; Abubakar Sha'aban; Mei Li Ng; Muhamad Ali Sk Abdul Kader; Dzul Azri Mohamed Noor; Baharudin Ibrahim Journal: Molecules Date: 2021-04-01 Impact factor: 4.411